Approximately 1.6 million patients undergo interhospital transfer annually.^[@bibr1-1178222619835548]^ Patients undergoing interhospital transfer experience up to three times higher mortality,^[@bibr2-1178222619835548],[@bibr3-1178222619835548]^ use double the resources and experience twice the length of stay than those not transferred from another hospital.^[@bibr1-1178222619835548]^ Interhospital transfers consist of two primary patient types: those experiencing an immediately life-threatening condition (e.g. myocardial infarction, trauma) and those who are not experiencing an immediately life-threatening condition. Transfer for patients experiencing an immediately life-threatening condition has been shown to be a life-saving measure, with reductions in mortality for trauma^[@bibr4-1178222619835548][@bibr5-1178222619835548][@bibr6-1178222619835548][@bibr7-1178222619835548]--[@bibr8-1178222619835548]^ and heart attack patients^[@bibr9-1178222619835548]^ but has yielded conflicting results for stroke^[@bibr10-1178222619835548],[@bibr11-1178222619835548]^ and minimally injured trauma patients.^[@bibr12-1178222619835548][@bibr13-1178222619835548]--[@bibr14-1178222619835548]^

The decision to transfer patients from lower to higher levels of care for an immediately life-threatening condition are common and often supported by referral networks established within local regions like trauma and stroke networks. For those patients not experiencing an immediately life-threatening condition, the decision to transfer is complicated and is based on individual provider judgment, family request, or other factors. Currently, no national guidelines^[@bibr15-1178222619835548]^ exists to guide interhospital transfer; furthermore, there is limited understanding of who does and does not benefit from being transferred and exactly when those transfers should occur.

The overall poor outcomes that interhospital transfer patients experience and mixed outcomes for patients that are immediately transferred for time-sensitive conditions suggest that we do not have a good understanding of immediately life-threatening conditions. Outside of patients that are transferred for intervention that must be performed immediately upon arrival at the receiving hospital (e.g. cardiac catheterization and surgical procedure), our recognition of what constitutes a patient experiencing an immediately life-threatening condition needs to be reconceptualized.

Reconceptualizing type of transfer patients require the focus to move beyond the currently used broad categories (e.g. trauma and stroke) to categories that support patient-specific characteristics that identify those who should be considered for transfer. Therefore, to begin moving toward a more patient-centric approach, the purpose of this study was to identify specific groups of patients and their associated characteristics that experience high levels of mortality post-transfer.

Methods {#section5-1178222619835548}
=======

Data source {#section6-1178222619835548}
-----------

We used the 2013 Nationwide Inpatient Sample (NIS). The NIS is part of the Healthcare Cost and Utilization Project (HCUP) from the Agency for Healthcare Research and Quality (AHRQ) and is the largest all-payer inpatient database in the United States with a nationally representative sample of approximately 8 million inpatient discharges each year.^[@bibr16-1178222619835548]^ We identified all adult patients aged 19 years or older that were transferred from one acute care hospital to another to compose an interhospital transfer cohort.

Measures {#section7-1178222619835548}
--------

Our main outcome measure is in-hospital mortality, as recorded on the hospital billing record discharge status. To identify patient characteristics and variables that are clinically meaningful and where available in the data set, we only incorporated covariates that are useful in guiding clinical decision-making or practice. Patient-level covariates included the following: age (continuous), gender, payer type, race, comorbidity, and primary diagnosis.

To include the primary diagnosis and to make the analysis computationally feasible, we accounted for the primary diagnosis via the Clinical Classification System (CCS) for the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM),^[@bibr17-1178222619835548],[@bibr18-1178222619835548]^ using the multi-level diagnosis category labels---a total of 17 categories. The multi-level CCS category is a standard, established method to collapse over 14 000 diagnosis codes and 3900 procedure codes into clinically meaningful categories.^[@bibr18-1178222619835548]^ Refer to [Supplementary Material Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1178222619835548) for variables included in analysis, for a listing of the covariates and CCS categories used in the model.

We measured the presence of comorbid conditions using the Elixhauser comorbidity index list. The Elixhauser index contains 30 comorbid conditions defined through secondary ICD-9-CM diagnosis codes and Diagnosis Related Group (DRG) codes.^[@bibr19-1178222619835548][@bibr20-1178222619835548]-[@bibr21-1178222619835548]^ We excluded both arthritis and fluid and electrolyte disorder comorbidities. Many patients have arthritis, and for the purposes of this study, it was not considered a factor that differentiates patients for transfer. In addition, most patients hospitalized and undergoing interhospital transfer experience some form of abnormal laboratory value, making it not clinically useful for identifying discrete subgroups of patients who will provide new insight to enable reconceptualizing patient categories for transfer.

To describe the severity of the patient population and to enabling comparison between the data subsets used in the analysis, we used the All Patient Refined Diagnosis Related Groups (APR-DRG) Risk Mortality covariate provided by HCUP. The APR-DRGs are assigned using proprietary software developed by 3M Health Information Systems that include the base APR-DRG, the severity of illness subclass, and the risk of mortality subclass within each base APR-DRG.^[@bibr16-1178222619835548]^ We only used this variable to provide a description of the study samples and did not include it in the model development and analyses due to it being a combination of other covariates already included in the model (e.g. age, gender, and diagnosis) while also including proprietary calculations that are not available within the electronic medical record (EMR) and thus would not be useable in decision-support tools or other patient care activities relying on primary data.

System-level covariates in the analysis included the following: admission month, admission on a weekend, hospital bed size, hospital teaching status, hospital region, hospital control/ownership, and patient location before hospitalization. We also accounted for whether patients received a major operating room procedure that was either diagnostic or therapeutic occurring post-transfer. The University Hospitals Case Medical Center Institutional Review Board determined that this study meets the exemption criteria for human subject research (IRB \#em-14-30).

Statistical analysis {#section8-1178222619835548}
--------------------

Frequency counts and percentages were tabulated for the categorical outcome---mortality. For descriptive analysis, we used discharge-level survey weights provided in the NIS that accounted for complex survey design effects. The final sample for this study is a nationally representative sample generated via the weighting variable provided with the data set. However, the classification and regression tree (CART) analysis does not apply the sample weights, which leads to smaller samples in the terminal nodes. We excluded cases where the mortality variable was missing. We did not exclude any observations with missing values for the independent variables specifically because a robust feature of the CART algorithm is that it handles missing data using the surrogate split method---a method that finds an alternative variable that is highly correlated with the missing variable to determine the split.^[@bibr22-1178222619835548]^ While there are other methods for handling missing data in CART analysis,^[@bibr23-1178222619835548]^ the default setting in CART packages is to skip missing variables to streamline the analysis.^[@bibr24-1178222619835548]^ In this analysis, we employed the surrogate split method that identifies and supplements a surrogate variable.

### Supervised machine-learning approaches {#section9-1178222619835548}

We used CART analysis to identify combinations of predictors associated with post-transfer mortality. The CART involves a tree-building technique in which the choice of "splitting" variables is based on an exhaustive search of all possibilities, using a recursive partitioning algorithm, resulting in mutually exclusive groups that are the most different with respect to the dependent variable.^[@bibr25-1178222619835548]^ The tree-building process leads to terminal nodes (or leaves), at which point the nodes cannot be divided anymore and need to be pruned to avoid over-fitting and increase efficiency.^[@bibr26-1178222619835548]^ First, CART recursively partitions the patients into smaller and smaller homogeneously distributed groups---in this case, based on the presence of specific combinations of clinical conditions. The purpose is to reduce variations within the group and to improve the fit as best as possible. Next, CART uses these groups to predict post-transfer mortality. We used the following stopping criteria (based on model tuning described below): a maximum tree depth of 10 splits, a minimum node size of 50 subjects, requiring a split to increase the complexity parameter by a minimum of 0.001 and using the information impurity index to determine node splits.

To build our model, we partitioned the study data into a training data set (70% of the data) and validation data set (remaining 30%) using random sampling within each class of the outcome variables. We used 10-fold cross-validation repeated three times on the training data set to build the CART models. Since mortality is highly unbalanced, we weighted the "cost" of a false negative to be higher than a false positive to improve sensitivity and produce a more meaningful model. We then tested the accuracy of our models on the testing data set using a confusion matrix and by calculating the area under the curve. We also used the Matthews correlation coefficient measure, a measure of accuracy that accounts for imbalanced outcomes.^[@bibr27-1178222619835548]^ We chose our final model for the outcome based on accuracy and interpretability.

In addition, we compared our final models with those from a random forest model to see if they were in agreement on variables that are the most important predictors. Random forest is a bootstrap aggregation method that creates multiple decision trees using random variable selection. Breiman et al^[@bibr22-1178222619835548]^ provides a detailed description of random forest. We used SAS software version 9.4^[@bibr28-1178222619835548]^ for data management; for our statistical analyses, we used R version 3.3.1 and RStudio 1.0.136^[@bibr29-1178222619835548]^ and the "rpart" (CART), partykit (tree graphics), "randomForest" (random forest), and "caret" (model tuning and cross-validation) packages.

Results {#section10-1178222619835548}
=======

In 2013, approximately 1 456 422 adult patients underwent interhospital transfer, 52% were male, 66% White, 11% Black, and 7% Hispanic. The primary payers for the interhospital transfer were Medicare 44%, Medicaid 19%, and private insurance 26%. Further demographic characteristics of the nationally weighted sample are provided in [Table 1](#table1-1178222619835548){ref-type="table"}, and the frequency of the primary diagnosis categorized by the multi-level diagnosis category of the CCS in [Table 2](#table2-1178222619835548){ref-type="table"}. As expected, circulatory disease was the most frequent diagnosis in the older age groups (45 and older), whereas mental health was the most frequent in the youngest age groups (19-44). Frequency of comorbidities across age cohorts is presented in [Table 3](#table3-1178222619835548){ref-type="table"}. The distribution of patient characteristics across the total study population and between the training and testing data sets are available in [Supplementary Material Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1178222619835548).

###### 

Sample characteristics[\*](#table-fn1-1178222619835548){ref-type="table-fn"}.

![](10.1177_1178222619835548-table1)

                             Age (19-34)   Age (35-44)   Age (45-54)   Age (55-64)   Age (65-74)   Age (75-84)   Age over 85                                                      
  -------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------ --------- ------ --------- ------ --------- ------
  Total subjects             179 895       125 525       212 665       275 530       290 259       245 504       127 044                                                          
  Sex                                                                                                                                                                             
   Male                      80 530        44.8          63 445        50.5          119 255       56            156 235       56.7   154 425   53.2   119 249   48.6   50 685    39.9
   Female                    99 360        55.2          62 075        49.5          93 400        43.9          119 295       43.3   135 830   46.8   126 239   51.4   76 344    60.1
  Race                                                                                                                                                                            
   White                     104 065       57.8          77 490        61.7          137 925       64.9          188 155       68.3   212 470   73.2   183 954   74.9   98 324    77.4
   Black                     27 440        15.3          17 425        13.9          29 795        14.0          32 750        11.9   23 950    8.3    15 515    6.3    6 495     5.1
   Hispanic                  16 675        9.3           10 155        8.1           14 070        6.6           14 535        5.3    13 620    4.7    11 710    4.8    5050      4.0
   Other                     31 715        17.6          20 455        16.3          30 875        14.5          40 089        14.6   40 219    13.9   34 324    14.0   17 175    13.5
  Admission status                                                                                                                                                                
   Non-elective admission    150 180       83.5          105 820       84.3          176 975       83.2          225 710       81.9   229 175   79.0   185 905   75.7   92 630    72.9
   Elective admission        29 015        16.1          19 230        15.3          35 055        16.5          48 955        17.8   60 104    20.7   58 684    23.9   33 859    26.7
  Mortality risk                                                                                                                                                                  
   Minor                     133 945       74.5          77 125        61.4          106 010       49.8          109 945       39.9   70 790    24.4   33 840    13.8   13 135    10.3
   Moderate                  22 550        12.5          23 660        18.8          50 490        23.7          75 700        27.5   92 070    31.7   89 624    36.5   50 949    40.1
   Major                     13 390        7.4           14 515        11.6          34 065        16.0          54 995        20.0   80 220    27.6   82 605    33.6   45 805    36.1
   Extreme                   9935          5.5           10 175        8.1           22 020        10.4          34 785        12.6   47 095    16.2   39 305    16.0   17 105    13.5
  Payer type                                                                                                                                                                      
   Medicare                  15 125        8.4           22 785        18.2          49 135        23.1          81 740        29.7   246 009   84.8   224 184   91.3   116 769   91.9
   Medicaid                  58 895        32.7          32 775        26.1          45 755        21.5          41 995        15.2   4040      1.4    2245      0.9    1045      0.8
   Private                   62 255        34.6          43 020        34.3          77 200        36.3          112 865       41.0   30 780    10.6   13 220    5.4    6015      4.7
   Self-pay                  25 765        14.3          16 385        13.1          24 620        11.6          19 480        7.1    1455      0.5    925       0.4    670       0.5
   Other                     14 305        8.0           8300          6.6           12 700        6.0           16 725        6.1    7265      2.5    4405      1.8    2335      1.8
  Hospital teaching status                                                                                                                                                        
   Nonteaching               44 000        24.5          30 335        24.2          51 405        24.2          65 450        23.8   74 775    25.8   70 215    28.6   39 500    31.1
   Teaching                  124 789       69.4          87 409        69.6          149 349       70.2          193 974       70.4   195 469   67.3   154 374   62.9   74 619    58.7
  Hospital region                                                                                                                                                                 
   Northeast                 25 900        14.4          18 500        14.7          32 320        15.2          40 530        14.7   42 525    14.7   36 855    15.0   21 085    16.6
   Midwest                   54 565        30.3          36 895        29.4          59 160        27.8          77 994        28.3   80 814    27.8   72 529    29.5   37 829    29.8
   South                     69 915        38.9          49 685        39.6          88 215        41.5          110 055       39.9   115 365   39.7   90 185    36.7   42 040    33.1
   West                      29 515        16.4          20 445        16.3          32 970        15.5          46 950        17.0   51 554    17.8   45 934    18.7   26 090    20.5

Sample characteristics total subjects and % represent the data set weighted to reflect national estimates.

###### 

Clinical classification frequencies[\*](#table-fn2-1178222619835548){ref-type="table-fn"}.

![](10.1177_1178222619835548-table2)

                            Age (19-34)   Age (35-44)   Age (45-54)   Age (55-64)   Age (65-74)   Age (75-84)   Age over 85                                                    
  ------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------ --------- ------ -------- ------ -------- ------
  Total subjects            179 895       125 525       212 665       275 530       290 259       245 504       127 044                                                        
  Clinical Classification                                                                                                                                                      
   Infection                5905          3.3           5740          4.6           11 615        5.5           16 780        6.1    16 685    5.7    12 785   5.2    6520     5.1
   Cancer                   2755          1.5           3525          2.8           8570          4.0           13 755        5.0    14 020    4.8    9745     4.0    3230     2.5
   Hematologic              2340          1.2           1365          1.0           1595          0.7           1995          0.7    2510      0.8    1675     0.7    2400     1.1
   Metabolic                3825          2.1           2870          2.3           4925          2.3           5470          2.0    4770      1.6    3200     1.3    1515     1.2
   Mental                   56 350        31.3          29 970        23.9          36 970        17.4          22 565        8.2    11 510    4.0    7445     3.0    4000     3.1
   Nervous                  7495          4.2           5395          4.3           7470          3.5           8235          3.0    7055      2.4    5175     2.1    1810     1.4
   Circulatory              10 695        5.9           21 480        17.1          56 110        26.4          88 615        32.2   100 700   34.7   83 435   34.0   37 355   29.4
   Respiratory              6165          3.4           5550          4.4           11 770        5.5           18 825        6.8    21 510    7.4    17 525   7.1    8980     7.1
   Digestive                12 735        7.1           11 840        9.4           19 380        9.1           23 360        8.5    23 195    8.0    18 685   7.6    10 295   8.1
   Genitourinary            3710          2.1           3780          3.0           5535          2.6           7425          2.7    8730      3.0    8035     3.3    4650     3.7
   Pregnancy                28 545        15.9          4745          3.8           80            0.0           0             0.0    0         0.0    0        0.0    0        0.0
   Skin                     2690          1.5           2085          1.7           2970          1.4           2765          1.0    2025      0.7    1535     0.6    795      0.6
   Musculoskeletal          2510          1.4           2520          2.0           3990          1.9           5000          1.8    5255      1.8    3870     1.6    1755     1.4
   Congenital               390           0.2           265           0.2           310           0.1           260           0.1    190       0.1    155      0.1    60       0.0
   Injury/poison            26 765        14.9          17 285        13.8          25 065        11.8          30 500        11.1   31 215    10.8   29 255   11.9   20 105   15.8

Sample characteristics total subjects and % represent the data set weighted to reflect national estimates.

###### 

Comorbidity Frequencies[\*](#table-fn3-1178222619835548){ref-type="table-fn"}.

![](10.1177_1178222619835548-table3)

                                        Age (19-34)   Age (35-44)   Age (45-54)   Age (55-64)   Age (65-74)   Age (75-84)   Age over 85                                                     
  ------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------ --------- ------ --------- ------ -------- ------
  Total subjects                        179 895       125 525       212 665       275 530       290 259       245 504       127 044                                                         
  Comorbidities                                                                                                                                                                             
   AIDS                                 345           0.2           465           0.4           910           0.4           480           0.2    170       0.1    45        0.0    0        0.0
   Alcohol abuse                        18 230        10.1          15 170        12.1          30 825        14.5          24 085        8.7    13 035    4.5    4735      1.9    750      0.6
   Deficiency anemias                   19 540        10.9          17 770        14.2          34 995        16.5          53 595        19.5   64 060    22.1   60 210    24.5   31 720   25.0
   Rheumatoid arthritis                 2410          1.3           2860          2.3           5255          2.5           8480          3.1    10 625    3.7    9390      3.8    3885     3.1
   Long-term blood loss anemia          5845          3.2           1895          1.5           1935          0.9           2995          1.1    3430      1.2    3205      1.3    1790     1.4
   Congestive heart failure             2455          1.4           3800          3.0           11 745        5.5           24 835        9.0    36 610    12.6   40 205    16.4   26 365   20.8
   Long-term pulmonary disease          18 770        10.4          16 435        13.1          40 600        19.1          66 610        24.2   78 965    27.2   61 535    25.1   24 755   19.5
   Coagulopathy                         7920          4.4           7515          6.0           16 735        7.9           23 745        8.6    23 920    8.2    19 760    8.0    8630     6.8
   Depression                           15 880        8.8           15 520        12.4          28 215        13.3          37 830        13.7   36 185    12.5   26 925    11.0   12 500   9.8
   Diabetes---uncomplicated             8810          4.9           16 465        13.1          43 640        20.5          73 310        26.6   89 275    30.8   68 140    27.8   25 630   20.2
   Diabetes---long-term complications   2305          1.3           4990          4.0           12 420        5.8           21 450        7.8    24 250    8.4    16 895    6.9    5065     4.0
   Drug abuse                           37 305        20.7          18 360        14.6          23 970        11.3          13 605        4.9    3840      1.3    1020      0.4    260      0.2
   Hypertension---combine               22 860        12.7          43 875        35.0          110 650       52.0          174 475       63.3   205 790   70.9   182 144   74.2   94 364   74.3
   Hypothyroidism                       6270          3.5           8785          7.0           18 920        8.9           30 870        11.2   42 890    14.8   44 915    18.3   28 720   22.6
   Liver disease                        3780          2.1           5240          4.2           13 805        6.5           17 185        6.2    10 215    3.5    4255      1.7    970      0.8
   Lymphoma                             400           0.2           590           0.5           1295          0.6           2440          0.9    3970      1.4    3175      1.3    1105     0.9
   Fluid and electrolyte disorders      27 630        15.4          26 510        21.1          54 190        25.5          78 815        28.6   86 100    29.7   74 350    30.3   39 365   31.0
   Metastatic cancer                    735           0.4           1350          1.1           4615          2.2           8390          3.0    9355      3.2    6090      2.5    1680     1.3
   Other neurological disorders         12 535        7.0           10 550        8.4           17 865        8.4           23 235        8.4    26 305    9.1    26 040    10.6   15 065   11.9
   Obesity                              18 115        10.1          21 465        17.1          37 150        17.5          49 950        18.1   45 995    15.8   22 575    9.2    4235     3.3
   Paralysis                            5980          3.3           5340          4.3           10 660        5.0           16 150        5.9    18 350    6.3    14 115    5.7    6345     5.0
   Peripheral vascular disorders        1695          0.9           2760          2.2           9880          4.6           22 780        8.3    34 320    11.8   31 790    12.9   14 300   11.3
   Psychoses                            11 940        6.6           9460          7.5           15 065        7.1           16 145        5.9    12 305    4.2    7985      3.3    3690     2.9
   Pulmonary circulation disorders      2340          1.3           2265          1.8           4965          2.3           8500          3.1    10 390    3.6    10 420    4.2    5645     4.4
   Renal failure                        4615          2.6           7660          6.1           19 875        9.3           38 770        14.1   55 325    19.1   56 865    23.2   31 255   24.6
   Solid tumor without metastasis       850           0.5           1045          0.8           3515          1.7           7005          2.5    9750      3.4    8040      3.3    3345     2.6
   Peptic ulcer disease                 15            0.0           40            0.0           65            0.0           90            0.0    120       0.0    115       0.0    15       0.0
   Valvular disease                     2095          1.2           2205          1.8           4635          2.2           8630          3.1    13 850    4.8    17 940    7.3    12 610   9.9
   Weight loss                          7105          3.9           6520          5.2           14 575        6.9           23 025        8.4    26 140    9.0    23 010    9.4    12 095   9.5

Sample characteristics total subjects and % represent the data set weighted to reflect national estimates.

The final CART identified 21 discrete subgroups of patients ([Figure 1](#fig1-1178222619835548){ref-type="fig"}). Trees from the training holdout data set and the testing holdout data set contained the same splits and terminal nodes. Of the 21 subgroups, 12 were for patients with a primary cardiac diagnosis (n = 16 798 patients), the next eight groups primary diagnoses were cancer (n = 35 030 patients), and the remaining subgroup had neither cardiac nor cancer as a primary diagnosis (n = 151 464).

![Classification and regression tree.\
The classification and regression tree with variables identified within the ovals and the value of each variable at the split signified and defined by each connecting line to the next variable and split. The bars at the bottom identify a distinct clinical group with the total number of subjects contained in that group (n), the bar represents the % mortality for patients in that group.](10.1177_1178222619835548-fig1){#fig1-1178222619835548}

Subgroups with a primary cardiac diagnosis ([Figure 1](#fig1-1178222619835548){ref-type="fig"}---right side) experiencing the highest rates of post-transfer mortality included (1) patients greater than 40 years old with either coagulopathy (30% mortality) or with metastasis (\~35%), (2) patients greater than 52 years old with cardiac arrhythmia and either liver failure (\~35%) or pulmonary circulatory comorbidity (30%), and (3) patients greater than 72 years without Medicare (35%). The payer mix of the patients in the subgroup that was greater than 72 years and without Medicare consisted of 10% on Medicaid, 56% private insurance, 10% self-pay, and 24% not specified. Alternatively, patients that were less than 40 years (5% mortality) or greater than 40 years and underwent an operating room procedure (5% mortality) experienced the highest rates of survival.

Subgroups of patients that had cancer as the primary diagnosis ([Figure 1](#fig1-1178222619835548){ref-type="fig"}---left side) that experienced the highest rates of mortality post-transfer included (1) those greater than 83 years old (35% mortality), (2) those \>68 years with either hypertension (15% mortality) or on Medicare (10% mortality), and (3) for those \<68 years old with coagulopathy and either arrhythmia (25% mortality) or pulmonary circulatory comorbidity (35% mortality).

The results from the random forest analysis are presented in [Figure 2](#fig2-1178222619835548){ref-type="fig"}. Variables identified as being important via random forest, but not included in any of the CART pathways include weight loss, congestive heart failure, and genitourinary.

![Random forest results.\
Abbreviations: Dx, diagnosis; CM, comorbidity.\
Variables identified as contributing the most to post-transfer mortality are displayed with the most important starting at the top and descending to least important. The highlighted box contains the variables with the highest importance. Variables with an \* are not included in the classification and regression tree.](10.1177_1178222619835548-fig2){#fig2-1178222619835548}

Model performance {#section11-1178222619835548}
-----------------

We tested the performance of our model on a holdout data set. The area under the curve was 0.69, and the Matthews correlation coefficient was 0.198. The model had a positive predictive value (PPV) of 0.291 and a negative predictive value (NPV) of 0.960. The sensitivity was 0.18 and the specificity was 0.98. As we further describe below, the aim of this model was to identify clinically meaningful rather than most accurately predict mortality post-transfer.

Discussion {#section12-1178222619835548}
==========

This analysis identified 21 distinct groups of patients, 13 of which experienced mortality rates more than double the national average ranging from 4.7% to 5.2% post-transfer mortality.^[@bibr1-1178222619835548]^ In 2013, the national mortality for all-cause hospital admissions was 2%. This analysis included all patients, even patients who underwent transfer for routine procedures such as orthopedic cases or appendectomies, who were accounted for in the far left of the tree in the lowest mortality group (n = 151 464). Alternatively, the other lowest mortality group consisted those with a circulatory diagnosis and who were aged younger than 40.5 years.

The left side of the tree, or the non-cardiac side, was dominated by patients with cancer, composing the second largest group of patients undergoing transfer (n = 35 020), with the highest mortality experienced by those with coagulopathy as a comorbid condition. Coagulopathy is also represented on the right side as significant contributor to increased mortality post-transfer. Of note, comorbid conditions in the AHRQ NIS are not directly related to the primary diagnosis or necessarily the main reason for admission, likely having originated before the current hospitalization, thus representing a pre-existing condition.^[@bibr16-1178222619835548]^ The finding that coagulopathy is a significant predictor of post-transfer mortality was surprising, but its significance is reinforced by the random forest analysis ([Figure 2](#fig2-1178222619835548){ref-type="fig"}) and our other work looking at surgical populations.^[@bibr30-1178222619835548]^ Coagulopathy typically manifests as a secondary physiologic response to a primary disturbance such as cancer and trauma induced and has been found to be an independent predictor of in-hospital mortality, regardless of transfer status.^[@bibr31-1178222619835548],[@bibr32-1178222619835548]^ This study reinforces including coagulopathy, whether it is a comorbidity or a condition on the active problem list for the current hospitalization, as a covariate in future modeling efforts.

This study identified that patients with a cardiac diagnosis and aged less than 40 years or were older than 40 years and received an operating room procedure experienced the highest survival rates post-transfer. While we cannot ascertain the specific operating room procedures performed, the high survival rates for this clinical group receiving a major therapeutic or diagnostic operating room procedure supports the role that transfer plays in improving mortality. Likely, these patients without concomitant comorbidity or other significant clinical characteristics, represent those experiencing a myocardial infarction or other time-sensitive condition that benefits from rapid transport and subsequent intervention.

While the primary focus of this study was not to predict patient mortality, the methods employed identified groups of patients that experience mortality at rates two to three times higher than the expected rate of post-transfer mortality of 5% and thus provides specific groups of patients that warrant focused inquiry. Current efforts to leverage EMR data to support developing clinical decision-support systems (e.g. health system transfer command centers)^[@bibr33-1178222619835548]^ can benefit by initially focusing on high-risk target populations like those identified in this analysis.

The random forest model identified several important variables not included in the individual tree, those being weight loss, congestive heart failure, and genitourinary conditions. The variable importance results reported in the random forest are the average results of many individual trees---many trees included the three omitted variables while others did not. Given that the CART tree represents an individual tree and sample; in this case sample, 789 out of 10 000, it is possible that variables identified in the random forest analysis are not represented in this specific tree. Omission of these variables in the individual tree can be due to the greedy splitting procedure that identifies the best split at that particular point in the tree without considering the impact on the full model. Therefore, depending on the random sample chosen to run the CART, the tree for each sample can include different variables and split points.

During the analytic process, we randomly select the samples and "freeze" them, otherwise we would get a different training and testing sample each time the analysis was performed. The omission of the variables underlines the importance of running complementary or additional analyses when using atheoretical approaches.

Our model had an area under the curve of 0.69, which is reasonable performance for rare and difficult events to predict like mortality. The area under the curve (AUC) is in-line with other studies that have used the Elixhauser or Charleston comorbidity indices to predict mortality that ranged between 0.65-0.80.^[@bibr34-1178222619835548],[@bibr35-1178222619835548]^ It is difficult to compare the performance of AUC across studies that assess different patient populations, and to our knowledge, this is the first model to predict mortality among all-diagnoses of transferred patients.

Finally, employing the supervised machine-learning techniques provides distinct analytical advantages over traditional modeling techniques that we have used in past analyses. The primary advantage is the ability to assess all available covariates in every possible combination. Rather than identifying the influence of a given covariate while the others are held constant, the supervised machine-learning techniques employed allow us to test every possible combination of the covariates to identify clinically meaningful combinations and report those combinations in mutually exclusive groups capable of being easily incorporated into decision-support modeling or other approaches such as developing more precise clinical nomograms. In addition, the mutually exclusive groups provide easily recognizable patient characteristics in specific combinations that are more descriptive than the odds of change in one variable while the others are held constant. For example, our past work employing regression identified that the odds of death increased with age, with age being included in the regression via seven categories.^[@bibr1-1178222619835548]^ Alternatively, in CART, we are able to include age as a continuous variable and let the technique determine what the significant splits in age are for a given combination of characteristics. For example, in [Figure 1](#fig1-1178222619835548){ref-type="fig"}, age is split five different times in the tree with each split signifying a significant difference in outcome for those patients above or below that age threshold. Attempting to identify these age categories via other approaches, would be burdensome, if achievable at all.

Limitations {#section13-1178222619835548}
-----------

Secondary analyses of existing databases present several limitations. First, we were only able to include basic demographic characteristics, the Elixhauser comorbidities, primary diagnosis via the CCS, and basic hospital descriptors. While nationally representative, the lack of rich clinical descriptors limits the depth of the analyses and applicability of the findings. Second, primary diagnosis determination is complex and is influenced by the clinical course of care as well as coding for payment. This well-known limitation has been identified by others. Third, we included all patients that were transferred between hospitals, including groups of patients that on one end would not impact overall transfer mortality rates (e.g. mental health) and, on the other end, patients who exceeded the level of care available at their current hospital (i.e. community hospital) and had to be transferred to a tertiary center. Fourth, inclusion of variables such as operating room procedure are only broad indicators of care and do not provide specificity in differentiating between normal and unexpected rates of mortality. However, the inclusion of operating procedure across the models highlights the need to conduct further in-depth investigations into specifically which transfers and corresponding procedures impart improved morbidity and mortality, highlighting a strength of this broad approach to focus future inquiry. Finally, we do not know why the patient was transferred and the elements contributing to the decision. This will be future work.

Conclusions {#section14-1178222619835548}
===========

This study analyzed a nationally representative sample of hospital discharges to identify groups of patients who experience increased mortality after undergoing interhospital transfer. The supervised machine-learning approach implemented identified 13 distinct groups of patients who experience post-transfer mortality more than double the national average mortality of post-transfer patients. Of the 13 groups, 10 experience mortality rates of 20% or greater, identifying specific groups of patients that may benefit from being transferred sooner based on their individual characteristics. The individual characteristics identified do not necessarily fall into the currently used categories of transfer patients, supporting the reconceptualization of which patient groups should be considered for immediate transfer to another hospital.
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